Your browser doesn't support javascript.
loading
Structural, functional, and immunogenicity implications of F9 gene recoding.
Katneni, Upendra K; Alexaki, Aikaterini; Hunt, Ryan C; Hamasaki-Katagiri, Nobuko; Hettiarachchi, Gaya K; Kames, Jacob M; McGill, Joseph R; Holcomb, David D; Athey, John C; Lin, Brian; Parunov, Leonid A; Kafri, Tal; Lu, Qi; Peters, Robert; Ovanesov, Mikhail V; Freedberg, Darón I; Bar, Haim; Komar, Anton A; Sauna, Zuben E; Kimchi-Sarfaty, Chava.
Afiliação
  • Katneni UK; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • Alexaki A; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • Hunt RC; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • Hamasaki-Katagiri N; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • Hettiarachchi GK; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • Kames JM; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • McGill JR; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • Holcomb DD; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • Athey JC; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • Lin B; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • Parunov LA; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • Kafri T; Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
  • Lu Q; Bioverativ, Waltham; MA.
  • Peters R; Bioverativ, Waltham; MA.
  • Ovanesov MV; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • Freedberg DI; Laboratory of Bacterial Polysaccharides, Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD.
  • Bar H; Department of Statistics, University of Connecticut, Storrs, CT; and.
  • Komar AA; Center for Gene Regulation in Health and Disease, Department of Biological, Geological and Environmental Sciences, Cleveland State University, Cleveland, OH.
  • Sauna ZE; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
  • Kimchi-Sarfaty C; Division of Plasma Protein Therapeutics, Hemostasis Branch, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US Food and Drug Administration (FDA), Silver Spring, MD.
Blood Adv ; 6(13): 3932-3944, 2022 07 12.
Article em En | MEDLINE | ID: mdl-35413099
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemofilia B Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemofilia B Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article